Transfusion and Haematology Today - Issue 1/2026
Editorial
Review/Educational Papers
16
28
37
Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
Z. Adam, J. Svojanovský, I. Svobodová, A. Tkadlec, M. Borský, M. Krejčí, M. Štork, I. Boichuk, Z. Král, L. Pour
Case Reports
48
Concurrent occurrence of BCR:: ABL1-positive chronic myeloid leukaemia and Philadelphia-negative myeloproliferative neoplasm
K. Slezáková, Z. Sninská, A. Bátorová, A. Žákovičová, R. Lukačková, Ľ. Majerová, J. Marcinek, P. Szépe, L. Plank, K. Rejleková
Best Practices
54
Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
M. Bohoněk, (STL), J. Bláha, (ČSARIM, ČSIM, ČSTH), A. Buliková, (ČHS), R. Češka, (ČIS), J. Gumulec, (ČSTH), Z. Kala, (ČCHS), T. Kuhn, (ČPS*), Luboš Kotík, (ČIS), J. Masopust, (STL), J. Malý, (ČNeoS), P. Mazánek, (ČPS*), R. Procházková, (STL), Martin Repko, (ČSOT), A. Truhlář, (SUMMK), M. Tuček, (ČSOT), K. Zdráhalová, (ČHS), P. Žák, (ČHS)
65
Recommendation of the Society for Transfusion Medicine No. 20 Cold red blood cell antibodies testing before cardiothoracic surgery on cardiopulmonary bypass
M. Králová, J. Masopust, M. Písačka, V. Řeháček, P. Turek
Non-Peer-Reviewed Contributions Supported by Commercial Funding
Transfusion and Haematology Today
2026 Issue 1
Most read in this issue
- Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
- Acute myeloid leukaemia – how the approach to diagnosis, risk stratification, and treatment options has changed
- Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
- What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses